SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.

Biotechnology

SparingVision

SparingVision's headquarters in Paris, France

Stéphane Boissel

Kali Stasi

Marie Uguen

Ryan Klimczak

Mehdi Gasmi

Rajiv Gangurde

José Alain Sahel

Jacque Duncan

Elias Arnér

Sabine Dandiguian

Paul Sieving

Laurent Arthaud

Masayo Takahashi

Botond Roska

Owen Smith

Jeanne Cunicelli

Bart Leroy

Jean Bennett

Eric Pierce

Thierry Léveillard

Pierre Chambon

Karen Wagner

Eyal Banin

Mark Pennesi

Joseph Papa

Rusty Kelley

Dominik Fischer

The Clinical Advisory and Project Management team at SparingVision plays a pivotal role in advancing the development of novel therapies for inherited retinal diseases. Comprising experienced clinical advisors and project managers, the team ensures that clinical trials are efficiently designed, executed, and monitored, while providing expert guidance on regulatory requirements and best practices. Their collaborative efforts are crucial in driving the research and development of SPVN06, facilitating successful interactions with stakeholders and ensuring the project's milestones are met.

Clinical Advisory and Project Management

The Finance and Corporate Development team at SparingVision is responsible for strategic financial management, capital allocation, and fostering partnerships to support innovative biotechnology projects. They analyze financial performance, oversee budgeting and forecasting, and ensure compliance while driving corporate growth initiatives and partnerships that enhance the development and commercialization of therapies for blinding inherited retinal diseases.

Finance and Corporate Development

The Scientific Advisors team at SparingVision plays a crucial role in guiding the research and development of therapies for inherited retinal diseases. Their expertise informs the design and execution of clinical trials, ensures compliance with regulatory standards, and supports the integration of cutting-edge scientific advancements into SparingVision's strategic initiatives, particularly for the development of SPVN06. Through collaboration within the team and with external stakeholders, they help translate scientific discoveries into viable treatment options for patients.

Scientific Advisors

The Leadership Team at SparingVision is responsible for guiding the company's strategic direction and ensuring alignment between its scientific, operational, and financial objectives. This team, comprised of key executives including the CEO, CMO, CTO, and CFO, collaborates to oversee the development of innovative therapies, drive fundraising efforts, and establish partnerships, all aimed at advancing treatments for blinding inherited retinal diseases like retinitis pigmentosa.

Leadership Team

The Regulatory and Quality Assurance team at SparingVision plays a crucial role in ensuring that the company's innovative therapies meet all regulatory requirements and quality standards throughout the development process. This team is responsible for navigating the complexities of regulatory submissions, maintaining compliance with health authority guidelines, and overseeing quality assurance processes to safeguard the integrity and safety of the products, ultimately facilitating their approval for clinical use.

Regulatory and Quality Assurance

SparingVision

Org chart

Board & advisors

Teams

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

Offices

SparingVision

Org chart

Board & advisors

Teams

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

Offices

Related companies